LUNAPHORE AND ACD REVOLUTIONIZE SPATIAL BIOLOGY RESEARCH WITH THE LAUNCH OF THE FIRST FULLY AUTOMATED, SAME-SECTION, HYPERPLEX MULTIOMICS APPLICATION
- Revolutionary spatial multiomics workflow
- Integration of RNA and protein data at the subcellular level
- Complete flexibility in panel design
- Commercial availability in Q2 2024
- None.
Insights
The introduction of a fully automated spatial multiomics workflow by Bio-Techne Corporation represents a significant advancement in the field of biomarker research and drug development. The ability to detect RNA and protein biomarkers on the same tissue section with high throughput and without manual intervention could greatly enhance the efficiency and reliability of translational research. This technological breakthrough has the potential to accelerate the discovery of predictive biomarkers and the development of targeted therapies, which is crucial for personalized medicine.
From a biotech industry perspective, the launch positions Bio-Techne as a leader in the spatial biology market, which could influence market share and competitive dynamics. The use of standard reagents, including clinically proven antibodies, suggests that the technology could be rapidly adopted in clinical research settings, potentially leading to quicker regulatory approvals and faster commercialization of new treatments. This could have a positive effect on Bio-Techne's revenue growth and market valuation in the medium to long term.
Given the increasing demand for precision medicine and the growing importance of biomarkers in therapeutic development, Bio-Techne's innovation could meet an unmet need in the market. The ability to provide a fully automated workflow with high throughput could attract a broad customer base, including pharmaceutical companies, clinical laboratories and academic institutions. The potential for this technology to streamline the research process and improve data robustness could lead to increased adoption rates, which would be a key driver of sales growth for Bio-Techne.
Furthermore, the announcement of this new product just before the Advances in Genome Biology and Technology (AGBT) 2024 General Meeting is a strategic move to generate industry buzz and attract potential customers. This could result in immediate business opportunities and partnerships, impacting the company's stock positively in the short term.
Investors will likely scrutinize the market response to Bio-Techne's new multiomics solution. The initial capital and R&D expenditure required for the development of such an advanced platform may have been substantial and stakeholders will be interested in the return on investment timeline. The company's future financial statements should be examined for increased sales revenue attributed to this product and any changes in the operational margins that reflect the product's profitability.
It is also important to consider the scalability of the COMET™ platform and its associated technologies. If the platform gains widespread acceptance, it could lead to recurrent revenue streams from reagent sales, software updates and service contracts. The financial impact of these factors could be significant, potentially leading to upward revisions of the company's earnings forecasts and a more favorable outlook from investors and market analysts.
Until now, researchers have faced challenges in integrating critical spatial information and accessing true multi-modal, same-cell analysis with full workflow automation. The Company's new multiomics solution for translational research overcomes this gap by enabling the correlation of RNA and protein data at the subcellular level in its spatial tissue context without any user intervention and with the highest throughput in the hyperplex market. This fully automated workflow enables researchers and clinicians to generate highly robust data through reliable and reproducible target detection. It offers complete flexibility in panel design by selecting any protein target with the use of standard reagents, including clinically proven IHC antibodies and RNAscope.
"Combining ACD's leading RNA detection technology with Lunaphore's fully automated high-throughput protein detection capabilities on the COMET system enables a best-in-class multiomics spatial biology solution," commented Kim Kelderman, Bio-Techne's Chief Operating Officer. "We remain focused on delivering breakthrough spatial technologies that empower researchers and clinicians to push boundaries in healthcare and ultimately improve patient outcomes. With this cutting-edge application, we continue to lead the way and shape the future of the spatial biology market."
The complete multiomics solution will be showcased through a series of activities at the Lunaphore Suite,
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated over
About COMET™
COMET™ is the only fully automated, high-throughput, hyperplex platform ensuring scalability and reproducibility without the need to conjugate primary antibodies. COMET™ provides walk-away automation, integrating staining, imaging, and image preprocessing steps to obtain standard hyperplex images. The multiomics capability of COMET™ enables the simultaneous analysis of both RNA and protein data within the spatial context of tissues to enhance the understanding of cellular dynamics and disease processes. COMET™ generates highly robust and reproducible data with full tissue preservation, allowing researchers to perform downstream modalities such as H&E or transcriptomics using the same slide. Its superior tissue profiling capabilities facilitate the analysis of 40 different spatial markers in each automated run on a tissue slide. In contrast to other spatial biology solutions, COMET™ works with off-the-shelf, label-free primary antibodies, making panel design much more flexible and faster than any other hyperplex solution. COMET™ works with regular glass slides from standard histology workflows; it is validated for human and mouse samples and is compatible with any other animal sample. The platform can be used for a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology. To learn more about the COMET™ platform, please visit: https://lunaphore.com/products/comet/
For further information on Lunaphore:
Lindsey Rodger, Head of Communications
communications@lunaphore.com
Bio-Techne Corporation (NASDAQ: TECH)
David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download multimedia:https://www.prnewswire.com/news-releases/lunaphore-and-acd-revolutionize-spatial-biology-research-with-the-launch-of-the-first-fully-automated-same-section-hyperplex-multiomics-application-302040724.html
SOURCE Bio-Techne Corporation
FAQ
What is the ticker symbol for Bio-Techne Corporation?
What is the new multiomics solution launched by Bio-Techne Corporation?
When will the multiomics application be commercially available?
What is the venue for the showcase of the complete multiomics solution?
